Skip to main content
GALECTIN THERAPEUTICS INC logo

GALECTIN THERAPEUTICS INC — Investor Relations & Filings

Ticker · GALT ISIN · US3632252025 LEI · 5299004HFYSAZM2ALW85 US Manufacturing
Open in API
Filings indexed 1,091 across all filing types
Latest filing 2020-09-09 Director's Dealing
Country US United States of America
Listing US GALT

About GALECTIN THERAPEUTICS INC

https://galectintherapeutics.com/

Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for fibrotic diseases, chronic liver disease, and cancer. The company's therapeutic approach centers on inhibiting the galectin-3 protein, which is implicated in various inflammatory, fibrotic, and malignant conditions. Its lead drug candidate, belapectin (GR-MD-02), is a proprietary carbohydrate-based drug designed to bind to and inhibit galectin-3. The primary development program for belapectin is focused on treating non-alcoholic steatohepatitis (MASH) with cirrhosis, a serious liver disease with no currently approved therapies.

Recent filings

Filing Released Lang Actions
FORM 4 SUBMISSION
Director's Dealing
2020-09-09 English
FORM 4 SUBMISSION
Director's Dealing
2020-09-09 English
FORM 4 SUBMISSION
Director's Dealing
2020-09-02 English
8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content includes the appointment of a new Chief Executive Officer, retirement of the previous CEO, expansion of the Board of Directors, and related agreements. There are no financial statements or detailed financial performance data included. The document primarily announces changes in senior management and board composition. Therefore, it fits the category of Board/Management Information (MANG). The document length is sufficient and contains detailed information about management changes, not just a brief announcement or press release. Hence, the classification is MANG with high confidence.
2020-09-02 English
FORM 8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated August 10, 2020, by Galectin Therapeutics Inc. It reports the results of operations and financial condition for the three and six months ended June 30, 2020, and includes a press release as an exhibit. The document states that the information is being furnished, not filed, pursuant to Item 2.02 of Form 8-K, which relates to Results of Operations and Financial Condition. The document is not a full quarterly or annual report but an initial announcement of financial results with a business update. This matches the definition of an Earnings Release (ER), which is the initial announcement of quarterly or periodical financial results with key highlights. The document length is 4569 characters, which is consistent with a press release and not a full report. Therefore, the correct classification is Earnings Release (ER).
2020-08-10 English
FORM 10-Q
Interim / Quarterly Report Q2 2020
2020-08-10 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.